333 related articles for article (PubMed ID: 20513599)
1. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.
Bailey D; Jahagirdar R; Gordon A; Hafiane A; Campbell S; Chatur S; Wagner GS; Hansen HC; Chiacchia FS; Johansson J; Krimbou L; Wong NC; Genest J
J Am Coll Cardiol; 2010 Jun; 55(23):2580-9. PubMed ID: 20513599
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Nicholls SJ; Gordon A; Johansson J; Wolski K; Ballantyne CM; Kastelein JJ; Taylor A; Borgman M; Nissen SE
J Am Coll Cardiol; 2011 Mar; 57(9):1111-9. PubMed ID: 21255957
[TBL] [Abstract][Full Text] [Related]
3. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.
Gilham D; Wasiak S; Tsujikawa LM; Halliday C; Norek K; Patel RG; Kulikowski E; Johansson J; Sweeney M; Wong NC; Gordon A; McLure K; Young P
Atherosclerosis; 2016 Apr; 247():48-57. PubMed ID: 26868508
[TBL] [Abstract][Full Text] [Related]
4. Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial.
Siebel AL; Trinh SK; Formosa MF; Mundra PA; Natoli AK; Reddy-Luthmoodoo M; Huynh K; Khan AA; Carey AL; van Hall G; Cobelli C; Dalla-Man C; Otvos JD; Rye KA; Johansson J; Gordon A; Wong NC; Sviridov D; Barter P; Duffy SJ; Meikle PJ; Kingwell BA
Metabolism; 2016 Jun; 65(6):904-14. PubMed ID: 27173469
[TBL] [Abstract][Full Text] [Related]
5. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.
Jahagirdar R; Zhang H; Azhar S; Tobin J; Attwell S; Yu R; Wu J; McLure KG; Hansen HC; Wagner GS; Young PR; Srivastava RA; Wong NC; Johansson J
Atherosclerosis; 2014 Sep; 236(1):91-100. PubMed ID: 25016363
[TBL] [Abstract][Full Text] [Related]
6. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.
Nicholls SJ; Gordon A; Johannson J; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJ; Wong NC; Borgman MR; Nissen SE
Cardiovasc Drugs Ther; 2012 Apr; 26(2):181-7. PubMed ID: 22349989
[TBL] [Abstract][Full Text] [Related]
7. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.
Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJ; Hu B; Uno K; Kataoka Y; Herrman JP; Merkely B; Borgman M; Nissen SE
Am J Cardiovasc Drugs; 2016 Feb; 16(1):55-65. PubMed ID: 26385396
[TBL] [Abstract][Full Text] [Related]
8. HDL subpopulations containing apoA-I without apoA-II (LpA-I) in patients with angiographically proven coronary artery disease.
Kuchta A; Strzelecki A; Ćwiklińska A; Gruchała M; Zdrojewski Z; Kortas-Stempak B; Wieczorek E; Gliwińska A; Dąbkowski K; Jankowski M
J Cardiol; 2017 Mar; 69(3):523-528. PubMed ID: 27169356
[TBL] [Abstract][Full Text] [Related]
9. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.
Kempen HJ; Asztalos BF; Moerland M; Jeyarajah E; Otvos J; Kallend DG; Bellibas SE; Wijngaard PL
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):736-42. PubMed ID: 26916733
[TBL] [Abstract][Full Text] [Related]
10. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
[TBL] [Abstract][Full Text] [Related]
11. A natural apolipoprotein A-I variant, apoA-I (L141R)Pisa, interferes with the formation of alpha-high density lipoproteins (HDL) but not with the formation of pre beta 1-HDL and influences efflux of cholesterol into plasma.
Miccoli R; Zhu Y; Daum U; Wessling J; Huang Y; Navalesi R; Assmann G; von Eckardstein A
J Lipid Res; 1997 Jun; 38(6):1242-53. PubMed ID: 9215551
[TBL] [Abstract][Full Text] [Related]
12. A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.
Naya N; Fukao K; Nakamura A; Hamada T; Sugimoto M; Kojima M; Yoshimura N; Uwabe K; Imagawa K; Nomura K; Hara S; Nakano T; Iwasaki T; Shinosaki T; Hanasaki K
Metabolism; 2016 Jan; 65(1):16-25. PubMed ID: 26683793
[TBL] [Abstract][Full Text] [Related]
13. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
Brousseau ME; Diffenderfer MR; Millar JS; Nartsupha C; Asztalos BF; Welty FK; Wolfe ML; Rudling M; Björkhem I; Angelin B; Mancuso JP; Digenio AG; Rader DJ; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1057-64. PubMed ID: 15761191
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of RVX-208 for the treatment of atherosclerosis.
Nikolic D; Rizzo M; Mikhailidis DP; Wong NC; Banach M
Expert Opin Investig Drugs; 2015; 24(10):1389-98. PubMed ID: 26364508
[TBL] [Abstract][Full Text] [Related]
15. RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases.
McNeill E
Curr Opin Investig Drugs; 2010 Mar; 11(3):357-64. PubMed ID: 20178050
[TBL] [Abstract][Full Text] [Related]
16. Influence of apolipoprotein A-I and apolipoprotein A-II availability on nascent HDL heterogeneity.
Alexander ET; Phillips MC
J Lipid Res; 2013 Dec; 54(12):3464-70. PubMed ID: 24089247
[TBL] [Abstract][Full Text] [Related]
17. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
[TBL] [Abstract][Full Text] [Related]
18. RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyond.
Ghosh GC; Bhadra R; Ghosh RK; Banerjee K; Gupta A
Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28423226
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.
Qin S; Liu T; Kamanna VS; Kashyap ML
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2428-34. PubMed ID: 17872455
[TBL] [Abstract][Full Text] [Related]
20. Effect of apolipoprotein A-I lipidation on the formation and function of pre-beta and alpha-migrating LpA-I particles.
Sparks DL; Frank PG; Braschi S; Neville TA; Marcel YL
Biochemistry; 1999 Feb; 38(6):1727-35. PubMed ID: 10026251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
